Notice of Intent to Publish a Funding Opportunity Announcement for Medications Development for the Treatment of Alcohol Use Disorder (AUD) or Alcohol-Related Organ Damage (AROD), or the Combination of AUD and AROD (U01 Clinical Trial Optional)

0
258

Opportunity ID: 322894
Opportunity Number: NOT-AA-19-032
Opportunity Title: Notice of Intent to Publish a Funding Opportunity Announcement for Medications Development for the Treatment of Alcohol Use Disorder (AUD) or Alcohol-Related Organ Damage (AROD), or the Combination of AUD and AROD (U01 Clinical Trial Optional)
Opportunity Category: Discretionary
Opportunity Category Explanation:
Funding Instrument Type: Cooperative Agreement
Category of Funding Activity: Health
Category Explanation:
CFDA Number(s): 93.273
Eligible Applicants: State governments
County governments
Independent school districts
Public and State controlled institutions of higher education
Native American tribal governments (Federally recognized)
Public housing authorities/Indian housing authorities
Native American tribal organizations (other than Federally recognized tribal governments)
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Private institutions of higher education
For profit organizations other than small businesses
Small businesses
Others (see text field entitled “Additional Information on Eligibility” for clarification)
Additional Information on Eligibility:
Agency Code: HHS-NIH11
Agency Name: Department of Health and Human Services
National Institutes of Health
Posted Date: Dec 04, 2019
Last Updated Date: Dec 04, 2019
Estimated Synopsis Post Date: Jan 15, 2020
Fiscal Year: 2020
Award Ceiling: $1,000,000
Award Floor:
Estimated Total Program Funding: $5,000,000
Expected Number of Awards: 4
Description: The National Institute on Alcohol Abuse and Alcoholism intends to promote a new initiative by publishing a Funding Opportunity Announcement (FOA) to solicit applications for research that advances promising compounds through the drug development pipeline for the treatment of Alcohol Use Disorder (AUD) or Alcohol-Related Organ Damage (AROD), or the combination of AUD and AROD. The aim of this FOA is to move candidate compounds through any single phase, or multiple phases of the development spectrum. For compounds focused on treating AUD or the combination of AUD and AROD, projects may start with lead optimization (late discovery) and go through Phase 2 proof-of-concept studies. For AROD, studies may start with lead optimization, but only go as far as Phase 1 safety tolerability trials. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. The FOA is expected to be published in winter 2020 with an expected application due date in spring 2020. This FOA will utilize the cooperative agreement U01 activity code. Details of the planned FOA are provided below.
Version: 1





Visit the Official Webpage For More Details on Notice of Intent to Publish a Funding Opportunity Announcement for Medications Development for the Treatment of Alcohol Use Disorder (AUD) or Alcohol-Related Organ Damage (AROD), or the Combination of AUD and AROD (U01 Clinical Trial Optional)

LEAVE A REPLY

Please enter your comment!
Please enter your name here